Direct answer: Acute pancreatitis is a potentially serious inflammation of the pancreas that usually requires urgent clinical assessment. Diagnosis generally requires at least two of three findings: characteristic upper-abdominal pain, amylase or lipase at least three times the laboratory’s upper limit of normal, or characteristic imaging. Lipase is the preferred blood enzyme in most acute evaluations, but an elevated result is not specific in every setting, a normal result does not answer every pancreatic question, and serial lipase values do not measure recovery. Lipase is not a wellness test, a chronic-pancreatitis screen, or a pancreatic-cancer test.[1][2]
Urgent care: Seek emergency assessment for sudden or severe persistent upper-abdominal pain—especially pain that spreads to the back—or pain with repeated vomiting, fever, rapid heartbeat, fainting, confusion, shortness of breath, jaundice, abdominal swelling, or inability to keep fluids down. Do not wait for an outpatient lipase result. Acute pancreatitis can worsen quickly and may require intravenous fluids, monitoring, imaging, and treatment of its cause.
This guide is a focused child of the Digestive Health Lab Tests pillar. Jaundice and biliary patterns are covered more broadly in the Liver Health as a Metabolic Dashboard pillar. Pancreatic malignancy belongs in the cancer pathway; see Pancreatic Cancer Symptoms and Testing: What Blood Tests Can—and Cannot Detect.
For general laboratory guidance, use The Complete Guide to Lab Tests and Blood Work, How to Read and Understand Your Lab Results, and Direct-Access Lab Testing: How It Works and What to Expect.
The pancreas lies behind the stomach. It releases digestive enzymes into the small intestine and hormones, including insulin, into the bloodstream. Pancreatitis means inflammation of this organ, but the course and testing depend on whether the process is acute or chronic.
| Condition | Core problem | Typical evaluation | Important distinction |
|---|---|---|---|
| Acute pancreatitis | Sudden pancreatic inflammation that can cause local or systemic complications | Symptoms, examination, lipase or amylase, cause-directed labs, and selected imaging | Often an urgent or hospital-level problem |
| Recurrent acute pancreatitis | More than one distinct acute episode | Confirm each episode and investigate gallstones, alcohol, triglycerides, calcium, medicines, anatomy, and genetic or autoimmune causes when appropriate | Recurrent attacks are not the same as continuous chronic pancreatitis |
| Chronic pancreatitis | Long-term structural damage and fibrosis | Cross-sectional imaging, endoscopic ultrasound or specialized testing, plus assessment for diabetes and EPI | Serum enzymes may be normal and do not reliably screen for chronic disease |
| Exocrine pancreatic insufficiency | Inadequate digestive-enzyme output causing maldigestion | Symptoms, nutrition assessment, and selected stool testing such as pancreatic elastase | EPI can result from chronic pancreatitis but is not synonymous with it |
| Pancreatic cancer | Malignant growth in the pancreas | Clinical assessment, pancreas-focused imaging, endoscopic ultrasound, and tissue sampling when needed | Lipase, amylase, CA 19-9, or a “pancreatic panel” cannot screen for or diagnose it alone |
The classic symptom is acute, persistent pain in the upper abdomen, often centered in the epigastrium and sometimes radiating to the back. Pain may be accompanied by nausea, repeated vomiting, fever, tenderness, rapid pulse, or abdominal swelling. Severe disease can affect the lungs, kidneys, circulation, and other organs.
Symptoms overlap with gallbladder disease, a perforated ulcer, bowel obstruction or ischemia, hepatitis, heart disease, and other emergencies. This is why a lipase number should never be used to triage severe abdominal pain at home.
Chronic pancreatitis may produce recurrent or persistent pain, weight loss, greasy or difficult-to-flush stool, diarrhea, vitamin deficiencies, and diabetes. Some people have less pain as the disease advances. Those patterns need planned gastroenterology evaluation rather than repeated acute enzyme panels.
Clinical guidelines use a two-of-three framework:
This is a clinical framework, not a self-diagnosis rule. The degree of enzyme elevation does not reliably grade severity, and other abdominal, kidney, medication-related, or systemic problems can raise lipase. Conversely, delayed presentation, advanced chronic damage, or marked hypertriglyceridemia can complicate enzyme interpretation.[1]
Lipase helps digest fat. When pancreatic acinar cells are injured, serum lipase can rise. Compared with amylase, lipase is generally more specific to pancreatic injury and stays elevated longer, making it the preferred enzyme for most suspected acute pancreatitis evaluations.
A marked elevation with characteristic pain strongly supports acute pancreatitis. Milder elevations are less specific and can occur with impaired kidney clearance, gallbladder or intestinal disease, some medicines, critical illness, and other conditions. The laboratory result must be interpreted against the assay-specific upper limit, timing, symptoms, kidney function, and imaging.
Lipase alone cannot:
Routine daily or repeated lipase testing after acute pancreatitis is established usually does not guide recovery. Clinicians follow pain, oral intake, vital signs, kidney and respiratory status, inflammatory course, and complications instead.
Amylase is produced by the pancreas and salivary glands. It may rise earlier and return toward normal sooner than lipase. Salivary disease, reduced kidney clearance, macroamylasemia, and other conditions can raise it. A normal amylase does not exclude acute pancreatitis when lipase or imaging is diagnostic, and adding amylase routinely to an already informative lipase result often contributes little.[1]
Additional testing is chosen to assess cause, complications, hydration, and organ function—not to create a universal “pancreatic panel.”
| Test | Why it may be selected | What it cannot establish alone |
|---|---|---|
| Complete Blood Count with Differential and Platelets | White-cell pattern, hemoconcentration, anemia, platelets, and infection/inflammation context | Cause, diagnosis, or severity of pancreatitis by itself |
| Comprehensive Metabolic Panel | Electrolytes, kidney function, glucose, calcium, proteins, and selected liver-associated markers | A normal CMP does not exclude pancreatitis; an abnormal CMP is not pancreas-specific |
| Liver Function Panel | Biliary obstruction or liver-associated pattern when gallstones are possible | Cannot show a stone, bile leak, or duct anatomy |
| Bilirubin Total and Bilirubin Direct | Characterize jaundice and impaired bile-flow patterns | Cannot identify where or why obstruction is occurring |
| Triglycerides | Investigate hypertriglyceridemia as a cause when not already known | A high value does not prove it caused the episode without compatible context |
| Calcium | Investigate hypercalcemia as a less common cause | A single abnormal value requires confirmation and cause-specific evaluation |
A CMP already includes total calcium and selected liver-associated markers. Avoid duplicating individual tests unless the clinical question or laboratory method requires it.
Ultrasound is commonly used early to look for gallstones and bile-duct dilation. It may not visualize the entire pancreas well because bowel gas and body habitus can limit the view.
Contrast-enhanced CT can show pancreatic inflammation, necrosis, fluid collections, and alternative diagnoses. The 2024 ACG guideline advises reserving early CT for an unclear diagnosis or lack of expected improvement rather than ordering it routinely in every obvious case. MRI and MRCP can evaluate the pancreas and bile/pancreatic ducts without ionizing radiation and may be useful in selected patients.[1][2]
Endoscopic ultrasound (EUS) can assess small stones, duct abnormalities, masses, and chronic changes when other studies do not answer the question. Endoscopic retrograde cholangiopancreatography (ERCP) is invasive and is generally used for a therapeutic indication, such as selected bile-duct obstruction or cholangitis, rather than as routine diagnostic imaging.
Gallstones and heavy alcohol use are common causes. Others include high triglycerides, high calcium, medicines, procedures, infection, trauma, anatomic abnormalities, autoimmune pancreatitis, and inherited susceptibility. Sometimes no cause is identified after initial testing.[3]
| Clue | Targeted follow-up |
|---|---|
| Gallstones, jaundice, or liver-associated abnormalities | Ultrasound and biliary imaging; specialist management when obstruction or cholangitis is possible |
| Heavy alcohol exposure | Candid, nonjudgmental exposure history and support for stopping alcohol |
| Very high triglycerides | Confirm level and assess diabetes, alcohol, medicines, pregnancy, and inherited lipid disorders |
| High calcium | Repeat/confirm and evaluate parathyroid or other causes |
| New medicine or dose change | Clinician/pharmacist review; do not stop essential medicines without guidance |
| Recurrent unexplained attacks | Gastroenterology assessment for microlithiasis, anatomy, genetic susceptibility, autoimmune disease, or other causes |
Chronic pancreatitis is a structural disease. Diagnosis often relies on CT, MRI/MRCP, EUS, and the clinical course. Serum lipase and amylase can be normal because damaged tissue may release fewer enzymes; normal levels do not reassure against chronic disease.
When greasy stool, unexplained weight loss, nutrient deficiency, or maldigestion suggests EPI, Pancreatic Elastase-1 can provide exocrine-function context. It is a stool test, not a blood enzyme. A low value supports EPI, but watery stool can dilute the sample and borderline results require clinical interpretation. AGA guidance considers values below 100 μg/g good evidence of EPI and 100–200 μg/g indeterminate; use the reporting laboratory’s interpretation and specialist guidance.[4]
EPI can be treated with prescribed pancreatic enzyme replacement and nutrition support when diagnosed. Do not use over-the-counter enzymes as a diagnostic trial for acute pain.
Pancreatitis does not mean pancreatic cancer. Chronic pancreatitis is associated with increased long-term cancer risk, but most people with pancreatitis do not have cancer. New jaundice, progressive weight loss, a pancreatic mass, a duct cutoff, or persistent unexplained symptoms may lead a clinician to a cancer-focused workup. Lipase and amylase cannot detect or exclude malignancy, and tumor markers are not substitutes for imaging and tissue evaluation. Use the separate pancreatic cancer symptoms and testing guide for that pathway.
In emergency evaluation, do not delay care to fast or to order tests online. In a planned outpatient cause assessment, follow the instructions for the complete order. Fasting may be required for triglycerides or other paired studies depending on the clinical question. Tell the clinician about alcohol, supplements, prescription and nonprescription medicines, recent procedures, gallstones, kidney disease, pregnancy, and prior attacks.
Severe or persistent abdominal pain, repeated vomiting, jaundice, fever, fainting, breathing difficulty, or dehydration requires clinical triage. A direct-access lipase result cannot provide intravenous treatment, determine organ failure, visualize a bile duct, or rule out another abdominal emergency. Even when an outpatient result is abnormal, the next step may be urgent care rather than adding more blood tests.
Lipase is generally the preferred enzyme for suspected acute pancreatitis, but the diagnosis requires clinical context and usually two of three criteria. No blood test alone evaluates every form of pancreatic disease.
No. The likelihood rises with a marked elevation and characteristic pain, but kidney disease, intestinal or biliary conditions, medicines, and critical illness can also raise lipase.
Yes, although it is uncommon early in a typical acute episode. Timing, advanced chronic pancreatic damage, and marked hypertriglyceridemia can complicate interpretation. Imaging and clinical judgment may be needed.
Not routinely once the diagnosis is established. Symptoms, vital signs, organ function, nutrition, and complications are more useful indicators of recovery.
No. Enzyme panels, tumor-marker bundles, and general blood work cannot screen for or diagnose pancreatic cancer. Suspicious symptoms need a cancer-focused clinical and imaging pathway.
Stool pancreatic elastase is commonly used when EPI is suspected. It evaluates digestive enzyme output and answers a different question from serum lipase in acute pain.
This article is educational and does not diagnose, treat, or replace urgent or specialist care. Laboratory findings must be interpreted with symptoms, examination, timing, medicines, organ function, and imaging. Ulta Lab Tests provides direct-access laboratory ordering and may receive revenue when readers purchase tests through links on this page. Product availability, components, preparation requirements, and reference intervals can change; confirm the current product page before ordering.
Originally published: July 25, 2023 | Substantively updated: September 2, 2026
Acute pancreatic-injury evaluation
Exocrine pancreatic function
Complication and organ-function context
These provide nonspecific blood-cell, electrolyte, kidney, glucose, calcium, and liver-associated context.
Possible biliary cause
These may support a bile-flow pattern but cannot show a gallstone or bile-duct anatomy.
Cause-directed testing
Ulta Lab Tests, LLC.
9237 E Via de Ventura, Suite 220
Scottsdale, AZ 85258
480-681-4081
(Toll Free: 800-714-0424)
